Camurus AB (NASDAQ: CAMX) announced on May 3, 2021, that the Australian TGA has approved significant label updates for its Buvidal® Weekly and Buvidal® Monthly injections. Key changes include a new 160 mg dose for Buvidal Monthly, allowing direct initiation onto Buvidal Weekly without prior sublingual treatment, and revised contraindications regarding pregnancy and lactation. This approval aligns with European labeling and aims to enhance treatment options for opioid dependence. In 2020, over 53,000 Australians received opioid dependence treatment, marking a 4.7% annual increase attributed to long-acting injectable treatments.
Camurus, based in Lund, Sweden, announced a positive opinion from the CHMP of the EMA for the marketing authorization of a new 160mg monthly dose of Buvidal (buprenorphine) for treating opioid dependence in patients aged 16 and older. This opinion signifies a significant advancement in treatment options within Europe, offering individualized dosing strategies. Buvidal, already a groundbreaking long-acting injectable treatment, has shown superior patient outcomes compared to daily sublingual alternatives. The final marketing authorization is expected from the European Commission by the end of May 2021.